Results 11 to 20 of about 102,850,963 (222)

A Dengue Virus Type 2 (DENV-2) NS4B-Interacting Host Factor, SERP1, Reduces DENV-2 Production by Suppressing Viral RNA Replication [PDF]

Viruses, 2019
Host cells infected with dengue virus (DENV) often trigger endoplasmic reticulum (ER) stress, a key process that allows viral reproduction, without killing the host cells until the late stage of the virus life-cycle.
Jia-Ni Tian, Chi-Chen Yang, Chiu-Kai Chuang, Ming-Han Tsai, Ren-Huang Wu, Chiung-Tong Chen, Andrew Yueh   +6 more
doaj   +5 more sources

Concurrent infection with dengue virus type-2 and DENV-3 in a patient from Ceará, Brazil

Memorias do Instituto Oswaldo Cruz, 2006
Dengue outbreaks have occurred in several regions in Brazil and cocirculating dengue virus type 1 (DENV-1), DENV-2, and DENV-3 have been frequently observed.
Fernanda Montenegro de Carvalho Araújo, Rita Maria Ribeiro Nogueira, Josélio Maria Galvão de Araújo, Izabel Letícia Cavalcante Ramalho, Maria Lucia Feitosa de Sá Roriz, Maria Elizabeth Lisboa de Melo, Ivo Castelo Branco Coelho   +6 more
doaj   +2 more sources

Computational prediction and analysis of envelop glycoprotein epitopes of DENV-2 and DENV-3 Pakistani isolates: a first step towards Dengue vaccine development.

PLoS ONE, 2015
Dengue fever of tropics is a mosquito transmitted devastating disease caused by dengue virus (DENV). There is no effective vaccine available, so far, against any of its four serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).
Hafsa Amat-ur-Rasool, Anam Saghir, Muhammad Idrees   +2 more
doaj   +2 more sources

DENV-3 precursor membrane (prM) glycoprotein enhances E protein immunogenicity and confers protection against DENV-2 infections in a murine model

Human Vaccines & Immunotherapeutics, 2021
To improve a DNA vaccine containing the truncated dengue virus serotype 2 (DENV-2) envelope (E) protein and evaluate the influence of precursor membrane (prM) glycoprotein polymorphism on E protein immunogenicity, two vaccine candidates have been ...
Roberto S. Dias, Michelle D. Teixeira, Mariana F. Xisto, John W. O. Prates, Jessica D. Da Silva, Iago O. Mello, Cynthia C. Da Silva, Sérgio O. De Paula   +7 more
doaj   +2 more sources

Phosphoproteome-Entailed Kinase-Substrate Landscape of Human-DENV-2 Interaction. [PDF]

Int J Mol Sci
Dengue virus (DENV) is a mosquito-borne RNA virus that causes serious illness in humans, ranging from mild fever to severe clinical manifestations, with dengue virus type 2 (DENV-2) being the most virulent among its four serotypes. Despite extensive research, no specific antiviral therapy is currently available, making the host-directed method an ...
Jabbar AA, Shaji V, Anil A, Nisar M, Soman S, Prasad G, Abhinand CS, Modi PK, Madanan MG, Jayanandan A, Pilankatta R, Raju R.   +11 more
europepmc   +3 more sources

Metabolic Screening and In Silico Investigation of Eucalyptus globulus Essential Oil Bioactives Against DENV-2 Envelope Protein. [PDF]

ChemistryOpen
Network pharmacology and molecular docking identify bioactive compounds from Eucalyptus globulus essential oil with potential activity against dengue virus, highlighting 70 shared targets and DENV‐2‐associated pathways. Globulol and eucalyptol show strong binding to DENV‐2 receptors, with favorable drug‐likeness and toxicity profiles, supporting their ...
Afzal A, Ahmad I, Mahadullah, Qamar S, Yousaf T, Ullah F, Khan D, Hamdard MH, Mashwani ZUR.   +8 more
europepmc   +2 more sources

A lethal DENV-2 wild-type mouse model for mutagenesis investigations. [PDF]

BMC Biol
Effective mouse models for testing antiviral medications should be both cost-effective and require minimal labor. Immunodeficient mouse models, such as AG129, are commonly used in dengue virus (DENV) research; however, their high import and maintenance costs make them relatively expensive. Moreover, the absence of IFN-γ signaling limits the capacity of
Qin Z, Xie X, Ye H, Wu H, Li Z, Li J, He X, Liang Z, Liu X, Zhu L, Wu Q, Xiao W, Wu K, Wan C, Zhang B, Sun Z, Yu J, Shen C, Yu L, Zhao W.   +19 more
europepmc   +3 more sources

A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells

Vaccine, 2023
Dengue is the most prevalent mosquito-borne viral disease and continues to be a global public health concern. Although a licensed dengue vaccine is available, its efficacy and safety profile are not satisfactory. Hence, there remains a need for a safe and effective dengue vaccine. We are currently developing a bivalent dengue vaccine candidate.
Mathurin, Seesen, Tuksin, Jearanaiwitayakul, Jitra, Limthongkul, Panuwat, Midoeng, Panya, Sunintaboon, Sukathida, Ubol   +5 more
openaire   +2 more sources

DENV 2 Infection v1

, 2023
En este protocolo se describen las condiciones para el mantenimiento de las líneas celulares C6/36 HT y BHK-21, además del procedimiento de infección y plaqueo del DENV 2
Edwin Stiven Quiguanás, Delia Piedad Recalde-Reyes   +1 more
openaire   +1 more source

Multiple arboviral infections during a DENV-2 outbreak in Solomon Islands [PDF]

Tropical Medicine and Health, 2020
Abstract Background Solomon Islands, a country made up of tropical islands, has suffered cyclic dengue fever (DF) outbreaks in the past three decades. An outbreak of dengue-like illness (DLI) that occurred in April 2016 prompted this study, which aimed to determine the population’s immunity status and identify the arboviruses circulating in the country.
Andrew Waleluma Darcy, Seiji Kanda, Tenneth Dalipanda, Cynthia Joshua, Takaki Shimono, Pheophet Lamaningao, Nobuyuki Mishima, Toshimasa Nishiyama   +7 more
openaire   +3 more sources